Thymic peptide
Thymosin Alpha-1
Thymosin alpha-1 has a serum half-life of approximately 2 hours after subcutaneous injection in the FDA's 2024 briefing document; the app lists 2 hours.1
Thymosin Alpha-1 after one dose: 50% at ~2 h, 25% at 4 h, 12.5% at 6 h.
Drawn from the half-life in the app's model, ~2 h. The model's figures
- Compound
- Thymosin Alpha-1
- Symbol
- TA1
- Family
- Healing peptides
- Parts
- 13
- References
- 17
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Thymosin alpha-1 (Ta1, thymalfasin) is a 28-amino-acid peptide that the FDA briefing describes as N-terminal acetylated and originally isolated from calf thymus.1 The same document calls thymalfasin a chemically synthesized version of Ta1, identical in amino acid sequence to the natural peptide, and describes Zadaxin as a finished drug product available in other countries.1 In the United States the briefing states that neither form of the substance is a component of an FDA-approved drug and that Ta1 has four orphan drug designations.1 It cites a 2014 company annual report for approvals in countries of the Asia-Pacific region, Latin America, Eastern Europe and the Middle East, mainly for hepatitis B infection and as a vaccine adjuvant, and adds that the FDA "is unable to independently verify these claims of approval in the specified countries".1
The app grades the evidence for thymosin alpha-1 as moderate. In TESTS, a placebo-controlled phase 3 trial in adults with sepsis, the authors report that the trial "found no clear evidence to suggest that thymosin α1 decreases 28 day all cause mortality in adults with sepsis".2 In a retrospective Hubei cohort of 2,282 eligible COVID-19 patients, 306 of whom received thymosin alpha-1, non-recovery was higher in the thymosin alpha-1 group in crude comparison (65/306 against 290/1,976, p = 0.003), and the authors state that the causal relationship between thymosin alpha-1 and a poor clinical outcome cannot be inferred.3 A 2026 Cochrane review of 10 randomised trials in chronic hepatitis B, with 1349 participants, rated the certainty of evidence as very low for all outcomes except serious adverse events, which it rated low.4
How it works
Sources in this part
The FDA briefing says the immunostimulant effects of Ta1 are proposed to be mediated at least in part by interaction with toll-like receptor 9 (TLR9) on dendritic cells and on lymphoid progenitor cells.1 In a mouse model of cytomegalovirus infection, the cited authors proposed that the antiviral effect ran through dendritic cell activation via the TLR9 and MyD88-dependent sensor, leading to activation of IFN regulatory factor 7 (IRF7).1 It describes the mechanisms independent of TLR as "poorly understood", and these findings come from cell and animal work.1 The ETASS authors describe Ta1 as having "a unique role in balancing pro- and anti-inflammatory cytokine production" through distinct Toll-like receptors and the MyD88-dependent pathway.5
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~2 h
- Bioavailability
- 90%
- Typical dose
- 1.6 mg/dose
- Route
- SubQ
- Time to peak
- ~2 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | About 2 hours | Serum half-life of approximately 2 hours after subcutaneous administration in the FDA briefing; mean elimination half-lives of 1.8 to 2.6 hours across three products in 9 healthy subjects (Rost and colleagues, 1999, as summarised in the briefing); the TESTS authors write that "the half life of the drug is 1.5 hours"1,2 |
| Bioavailability | 90% | No bioavailability percentage appears in the pharmacokinetic section of the FDA briefing, and the app's own note calls its value an estimate1 |
| Time to peak | About 2 hours | Tmax of approximately 2 hours in the briefing's summary; individual Tmax values of 0.67 to 2 hours across three products, and Cmax values of 32.6 to 78.9 µg/L, after a single 900 µg/m2 subcutaneous dose1 |
After daily dosing for five days the briefing reports "no evidence of accumulation", and it gives endogenous serum levels in healthy adults as 0.1-1 ng/mL.1 The briefing's other human pharmacokinetic study, preliminary results from a randomized, double blind phase 2 study by Schulof and colleagues (1984) in 42 subjects with locally advanced non-small cell lung cancer, reported that plasma levels increased 10-fold 1 hour after a single dose, that peak levels persisted for approximately 6 hours, and that they returned to near baseline over the next 18 hours.1
Level over 6 weeks
Level, as a share of the peak after one 100 mg dose
As studied: every 12 hours for up to 7 days (TESTS)2, twice weekly, doses 3 days apart (Indonesian label as summarised by the FDA)1, twice weekly, doses 4 days apart (Indonesian label as summarised by the FDA)1.
An illustration from a pharmacokinetic model using a half-life of 2 hours. It is not a measured level or a suggested dose.
Human studies
Rows below come from full texts (TESTS, ETASS, the COVID-19 cohort) or from the PubMed record only (the other trials and reviews).
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Wu and colleagues, TESTS, BMJ 20252 | Multicentre, double-blind, placebo-controlled phase 32 | 1106 adults aged 18-85 years with sepsis (Sepsis-3), 22 centres in China; 1089 in the modified intention-to-treat analyses2 | Thymosin α1 or placebo subcutaneously every 12 hours for up to 7 days2 | 28-day mortality 127 (23.4%) of 542 on thymosin α1 against 132 (24.1%) of 547 on placebo; serious adverse events 145 (26.8%) against 160 (29.3%); no secondary outcome differed significantly2 |
| Wu and colleagues, ETASS, Critical Care 20135 | Multicentre, single-blind randomised trial; patients and statistician blinded5 | 361 adults with severe sepsis in ICUs of six teaching hospitals in China (180 control, 181 thymosin alpha-1)5 | 1.6 mg twice daily for 5 days, then once daily for 2 days, against saline5 | 28-day mortality 26.0% against 35.0%, relative risk 0.74 (95% CI 0.54 to 1.02); CD4+/CD8+ ratio did not differ; no serious drug-related adverse event5 |
| Liu and colleagues, Frontiers in Immunology 20213 | Retrospective multicentre cohort, five hospitals in Hubei, December 2019 to March 20203 | 2,282 adults with COVID-19; 306 received thymosin alpha-1, 1,976 did not3 | Any subcutaneous or intramuscular thymosin alpha-1 during the hospital stay; dose not specified3 | Adjusted odds ratio for non-recovery 1.5 (95% CI 1.1 to 2.1, p = 0.028); not significant after adding maximum SOFA score (OR 1.4, 95% CI 0.9 to 2.2, p = 0.118)3 |
| Soeroto and colleagues, Inflammopharmacology 20236 | Systematic review and meta-analysis of 8 studies6 | People with moderate to critical COVID-196 | Varied by study6 | Mortality risk ratio 0.59 (95% CI 0.37 to 0.93, I2 = 84%); no difference in mechanical ventilation (RR 0.83, 0.48 to 1.44) or hospital stay6 |
| Kim and colleagues, Scandinavian Journal of Gastroenterology 20127 | Prospective multicentre open-label randomised trial7 | 51 patients with HBeAg-positive chronic hepatitis B (26 combination, 25 monotherapy)7 | 1.6 mg twice a week for the first 12 weeks plus peginterferon α-2a 180 μg weekly for 48 weeks, against peginterferon alone7 | Combined response (HBeAg seroconversion, HBV DNA suppression and normalization of serum ALT) at end of treatment 4/26 (15.4%) against 3/25 (12.0%), p = 0.725; at end of follow-up 6/26 (23.1%) against 5/25 (20.0%), p = 0.7897 |
| Lee and colleagues, Journal of Gastroenterology and Hepatology 20088 | Prospective randomised pilot study8 | 67 HBeAg-positive naïve patients with chronic hepatitis B (34 combination, 33 lamivudine)8 | 1.6 mg twice a week for 24 weeks plus lamivudine 100 mg daily, then lamivudine alone8 | HBeAg seroconversion at 24 weeks 26.5% against 6.1% (P = 0.024); at 52 weeks 26.5% against 12.1% (P = 0.138); viral breakthrough at 52 weeks 35.3% against 21.2% (P = 0.201)8 |
| Wu and colleagues, Expert Opinion on Biological Therapy 20189 | Prospective multicentre open-label randomised trial9 | 690 patients with hepatitis B-related compensated cirrhosis (351 combination, 339 entecavir)9 | Thymosin alpha-1 plus entecavir for 52 weeks after 26 weeks of entecavir; dose not given in the record; median follow-up 38.2 months9 | Cumulative incidence of liver decompensation, hepatocellular carcinoma or death was similar between groups; hepatocellular carcinoma incidence during combination treatment 1.7% against 2.1%; the record states both therapies were well-tolerated9 |
| Naing and colleagues, Cochrane Database of Systematic Reviews 20264 | Systematic review and meta-analysis of 10 randomised trials4 | 1349 randomised adults with chronic hepatitis B4 | Any dose, route or formulation; follow-up 6 months to 5 years after treatment (median 12 months)4 | May reduce all-cause mortality (RR 0.53, 95% CI 0.29 to 0.96; 3 studies, 907 participants; very low-certainty evidence) and serious adverse events (RR 0.72, 0.53 to 0.99; 5 studies, 1056 participants; low-certainty evidence); non-serious adverse events RR 0.47 (0.27 to 0.83; very low-certainty evidence); quality of life MD 0.70 (-2.55 to 3.95; 1 study, 161 participants) and histological improvement RR 0.51 (0.13 to 2.06), both described as little to no effect; the authors write that they are not sure whether thymosin-α1 reduces all-cause mortality or adverse events4 |
| Maio and colleagues, Journal of Clinical Oncology 201010 | Randomised, five treatment groups, with dacarbazine10 | 488 people with metastatic melanoma10 | Thymosin alpha-1 1.6, 3.2 or 6.4 mg with dacarbazine and interferon alfa, or 3.2 mg with dacarbazine alone, against dacarbazine plus interferon alfa; up to 24 months of observation10 | Best overall response at 12 months: 10 and 12 responses in the two 3.2 mg arms against 4 in controls; median overall survival 9.4 months in patients given thymosin alpha-1 against 6.6 months in the control group (dacarbazine plus interferon alfa), P = .08; the record states that adding thymosin alpha-1 did not lead to any additional toxicity10 |
| Liu and colleagues, GASTO-1043, Int J Radiat Oncol Biol Phys 202211 | Phase 2 single-arm trial with propensity-matched historical controls11 | 69 adults with unresectable locally advanced non-small cell lung cancer, 69 matched controls11 | Weekly thymosin α1 from the start of chemoradiotherapy until 2 months after it; dose not given in the record11 | Grade 2 or higher radiation pneumonitis 36.2% against 53.6% (P = .040)11 |
Deeper analysis: TESTS (sepsis)
Wu and colleagues reported TESTS in the BMJ in 2025 as a multicentre, double-blind, placebo-controlled phase 3 trial at 22 centres in China between September 2016 and December 2020.2 The registry lists Sun Yat-sen University as lead sponsor, Wu Jianfeng of that university as responsible party, and SciClone Pharmaceuticals, class industry, as a collaborator.13 The FDA briefing describes SciClone Pharmaceuticals as "the manufacturer of Zadaxin".1 Of 1106 adults enrolled, 1089 entered the modified intention-to-treat analysis (542 on thymosin α1, 547 on placebo).2 The primary outcome, 28-day all-cause mortality, occurred in 127 (23.4%) on thymosin α1 and 132 (24.1%) on placebo, with a hazard ratio of 0.97 (95% CI 0.76 to 1.24, P=0.82) in the PMC full text.2 The PubMed record of the same paper gives that hazard ratio as 0.99 (95% CI 0.77 to 1.27; P=0.93), so the two versions of the paper differ on this figure.2 Ninety-day mortality was 31.0% against 32.4% (hazard ratio 0.95, 0.77 to 1.17, P=0.61).2 Prespecified subgroups showed higher 28-day mortality on thymosin α1 in people under 60 years (hazard ratio 1.67, 1.04 to 2.67) and a lower one in people with diabetes (0.58, 0.35 to 0.99), with P for interaction 0.01 and 0.04.2 For participants aged 60 and older the hazard ratio was 0.81 (0.61 to 1.09).2 The paper states a Bonferroni significance threshold of P=0.006 for the subgroup analyses, and a post hoc adjustment for organ support gave 1.45 (0.89 to 2.36) in people under 60.2 In exploratory immune markers the neutrophil to lymphocyte ratio change favoured thymosin α1 (percentage change group difference −9%, −15% to −2%, P=0.006), with no between-group difference in monocyte HLA-DR or regulatory T cells.2 Adverse events occurred in 360 (66.4%) on thymosin α1 and 370 (67.6%) on placebo, and serious adverse events in 145 (26.8%) and 160 (29.3%).2 The most common were anaemia (10.7%), fever (9.6%), abdominal distension (5.4%) and coagulation disorders (4.8%), and the authors report no unexpected serious adverse events related to thymosin α1.2 The authors name three limitations: heterogeneity of sepsis, that "our study may have been underpowered", and that most enrolled patients "were likely not in the early stages of sepsis".2 They add that the sample size assumed 27% against 35% mortality and "in retrospect, this might have been too ambitious".2 The trial was funded by the Sun Yat-sen University Clinical Research Program 5010, the Guangdong Clinical Research Center for Critical Care Medicine and SciClone Pharmaceuticals.2 Twelve authors, listed by initials, declare grants from SciClone Pharmaceuticals, and three declare consultancy fees from it and other companies.2
Deeper analysis: ETASS (severe sepsis)
The Zadaxin brand from SciClone Pharmaceuticals is named as the study drug, and the authors "declare that they have no competing interests".5 It was funded by the Sun Yat-sen University Clinical Research Program 5010, and the authors add that the work was in part supported by the Guangdong Natural Science Foundation and the Guangdong Medical Scientific Research Foundation.5 The 28-day mortality difference was marginal (P = 0.062 non-stratified, 0.049 log rank), and the sample size had assumed a fall from 50% to 35%.5 Among the secondary results, the authors report decreased in-hospital mortality (P = 0.032) and a greater improvement of monocyte HLA-DR on day 3 and day 7 in the thymosin alpha-1 group than in the control group.5 At baseline the thymosin alpha-1 group had a longer interval from first organ dysfunction to enrolment (42 hours against 28 hours, P = 0.003) and lower monocyte HLA-DR (47.1% against 58.0%, P = 0.02).5 The authors list as limitations that they "did not adopt the double-blind method because no identical-appearing placebo was available", and call the work "a preliminary exploration".5 On safety, no treatment was discontinued due to intolerance or adverse events, but the authors note that subjective sensations such as irritation or burning, general or gastrointestinal disorders were difficult to assess because of the severity of disease, sedation or analgesia in severe sepsis patients.5
Deeper analysis: the COVID-19 cohort
Liu and colleagues, in Frontiers in Immunology in 2021, studied adults admitted to five designated hospitals in Hubei between 29 December 2019 and 16 March 2020, with informed consent waived because the study was retrospective.3 Crude outcomes were higher in the thymosin alpha-1 group: non-recovery 65/306 against 290/1,976, in-hospital mortality 62/306 against 271/1,976 and intubation 31/306 against 106/1,976.3 Adjusted for confounders the odds ratio for non-recovery was 1.5 (95% CI 1.1 to 2.1, p = 0.028), but it became non-significant (OR 1.4, 95% CI 0.9 to 2.2, p = 0.118) once maximum SOFA score was added.3 After 1:3 propensity matching, non-recovery was 65/306 against 111/720 (p = 0.024); the association was significant in the subgroup with maximum SOFA score of 2 or more (OR 2.0, 95% CI 1.4 to 2.9) and not significant in the subgroup with a score below 2 (OR 0.6, 95% CI 0.24 to 1.7), with a significant interaction (p = 0.024).3 The authors list as limitations that use "was mainly at the discretion of clinicians" and that confounding bias "remains possible".3 Funding was from the National Natural Science Foundation of China, and the authors declare no commercial or financial relationships that could be construed as a potential conflict of interest.3 The meta-analysis of 8 COVID-19 studies points the other way on mortality, and its authors write that randomised trials "are still required to verify the findings".6
Hepatitis B and other settings
The FDA briefing cites small size and design limits in hepatitis B studies, such as lack of control group, outdated therapy in the control arm and lack of blinding.1 In the Cochrane review, four trials were funded by industry, five by research grants and one gave no information.4 The Kim authors concluded that short-term addition of thymosin α-1 "was not superior to peginterferon α-2a alone" on antiviral efficacy.7 In the melanoma trial, the progression-free survival hazard ratio was 0.80 (95% CI 0.63 to 1.01; P = .06) for thymosin alpha-1 groups against control; funding is not stated in the PubMed record.10 The lung cancer trial authors write that its result was "compared with historic controls".11 A 2026 scoping review of 26 clinical publications in cancer, mostly retrospective observational studies and case reports from China, reports that heterogeneity limited comparability and that "prospective controlled studies" are needed.12
Doses reported in studies and on labels
| Source | People and n | Dose and route | Length and comparator |
|---|---|---|---|
| FDA briefing, summary of clinical studies1 | Varied; trials with Ta1 alone or with antiviral and anticancer drugs1 | Daily doses of 0.6 to 9.6 mg/m2 (about 1 to 16 mg at a mean 1.7 m2), usually subcutaneous on a biweekly schedule; most common dose 1.6 mg subcutaneously1 | 1 day to 12 months1 |
| Rost and colleagues 1999 (via FDA briefing)1 | 9 healthy subjects, three-way crossover1 | 900 µg/m2 subcutaneously (actual 1.6 to 2.2 mg)1 | Days 1, 3, 4, 5, 6 and 7 of each 7-day period1 |
| TESTS, sepsis2,13 | 1106 randomised adults; 1089 analysed2 | 1.6 mg subcutaneously every 12±2 hours13 | Up to 7 days, against placebo2 |
| ETASS, severe sepsis5 | 361 adults5 | 1.6 mg subcutaneously twice daily, then once daily5 | 5 days then 2 days, against saline5 |
| Kim 2012 and Lee 2008, hepatitis B7,8 | 51 and 67 adults7,8 | 1.6 mg subcutaneously twice a week7,8 | 12 weeks with peginterferon (Kim) or 24 weeks with lamivudine (Lee)7,8 |
| Italian Zadaxin label, as summarised in the FDA briefing1 | Immunocompromised people, as an adjuvant to influenza vaccination1 | One 1.6 mg vial subcutaneously or intramuscularly, twice weekly1 | Four weeks from the first vaccination, repeated from the eighth to twelfth week1 |
| Indonesian Zadaxin label, as summarised in the FDA briefing1 | Chronic hepatitis B, age 18 or older, compensated liver disease, serum HBV DNA positive1 | 1.6 mg subcutaneously twice weekly, doses 3 or 4 days apart1 | Six months (52 doses) without interruption1 |
Side effects reported
Sources in this part
The FDA briefing concludes that in most clinical studies Ta1 "has been found to be well-tolerated" at 1 to 16 mg subcutaneously for up to 12 months, with local irritation, redness or discomfort at the injection site the most common reactions.1 In the same conclusion the FDA states that use of Ta1-related bulk drug substances in compounding may raise safety concerns, and that it is not clear whether administration of Ta1 in patients undergoing HSCT could lead to the development or worsen acute or chronic graft-versus-host disease or lead to engraftment failure.1 It adds that in many studies no adverse events attributable to Ta1 were reported, and that some vaccine-adjuvant trials gave limited description of adverse event types.1 A search of the FDA Adverse Event Reporting System to 10 June 2024 retrieved one applicable report, in a 46-year-old male also receiving peginterferon alfa-2a, who was hospitalized with anxiety, atrial fibrillation and a transient decrease in thyroid-stimulating hormone levels and was discharged the following day; the briefing calls causality "confounded" by the peginterferon alfa-2a, says it cannot make definitive conclusions on safety from FAERS data alone, and reports that a CAERS search yielded zero cases.1 It also states that for a compounded product, formulation, concentration and storage may favour impurities and aggregates "capable of inducing untoward immunogenic responses".1 The Italian label as summarised there states that Zadaxin is not for use in children and is contraindicated during pregnancy and lactation, and that it has not led to clinically appreciable side effects "except for the occasional possibility of a modest and transient pain" at the injection site.1 The Indonesian label as summarised there describes a transient ALT increase to more than twice baseline (flare) during therapy, and calls use in deliberately immunosuppressed people, such as organ transplant patients, as contraindicated unless the potential benefits clearly outweigh the risks.1 In trials, TESTS reported adverse events in 66.4% on thymosin α1 against 67.6% on placebo and serious adverse events in 26.8% against 29.3%, and the Cochrane review reported a serious adverse events risk ratio of 0.72 (95% CI 0.53 to 0.99; low-certainty evidence) and a non-serious adverse events risk ratio of 0.47 (95% CI 0.27 to 0.83; very low-certainty evidence) in hepatitis B trials.2,4 Kim and colleagues report no significant differences in adverse events.7 The scoping review states that safety reporting was inconsistent and describes one case of severe multisystem immune-related toxicity during combination treatment, without establishing a Tα1-specific cause.12
Bloodwork and markers
Sources in this part
The app lists CD4 count, CD8 count, absolute lymphocytes, white blood cell count and hs-CRP as markers to monitor. In ETASS, CD4+/CD8+ was measured on days 0, 3 and 7, and the authors "did not find statistically significant difference in the CD4+/CD8+ ratio between the two groups".5 In TESTS, the day-7 lymphocyte count was a median 0.96 against 0.91 (difference 0.06, 0 to 0.14; P 0.07), an exploratory outcome.2 No white blood cell count or hs-CRP outcome appears in the TESTS outcomes table.2 In the lung cancer trial, the median lymphocyte nadir was 0.51 k/µL against 0.30 k/µL in matched controls, and the share with maximum CRP of 100 mg/L or more was 13.8% against 29.7%; the record names CRP, not hs-CRP.11 In the COVID-19 cohort, the change in lymphocyte count was comparable between groups (p = 0.337), although initial and minimal counts were lower in the thymosin alpha-1 group.3
Regulatory and anti-doping status
Sources in this part
The FDA briefing states that no USP or National Formulary monograph applies to Ta1 and that neither form is a component of an FDA-approved drug.1 It records that the Wells Pharmacy Network nomination for the 503A bulks list was withdrawn, and that the FDA evaluated Ta1 free base and Ta1 acetate on its own initiative.1 The briefing says the FDA believes "the evaluation criteria weigh against placing" both forms on the 503A bulks list.1 The briefing's cover note says the FDA will not issue a final determination until input from the advisory committee process has been considered.14 The December 2024 draft questions asked the Pharmacy Compounding Advisory Committee to vote on the FDA proposal that thymosin alpha-1 (free base) and thymosin alpha-1 acetate not be included on the 503A Bulks List.15 In the transcript, the first question, on voting as a group, was recorded as 20 yeses and 1 no, after which the committee voted on each substance separately.16 The transcript records 4 yeses, 17 noes and 0 abstentions twice, once after the question on the free base and once after the later question, where a yes was a vote to place the substance on the list.16 A search of the European and Japanese Pharmacopoeias "did not show any monograph listings for Ta1 or Ta1 acetate".1 The 2026 WADA Prohibited List, in effect from 1 January 2026, names "Thymosin-ß4 and its derivatives e.g. TB-500" in section S2.3, which is introduced as "including, but not limited to".17 Thymosin alpha-1 and thymalfasin do not appear by name in the text of that list as retrieved, so the list's wording does not itself settle the status of an unnamed substance.17
What is not known
Sources in this part
No bioavailability percentage for subcutaneous thymosin alpha-1 appears in the FDA briefing's pharmacokinetic section, which identified two human pharmacokinetic studies.1 The FDA reports that its search of published literature "did not reveal studies in which compounded drug products containing Ta1" were used in humans.1 The FDA says that although Ta1 is approved for HBV infection in other countries, "we do not know the current extent of its use".1 The sources used for this compound do not include the FDA's final determination after the December 2024 vote, and no thymalfasin label was identified on DailyMed in a search for the term.14
Frequently asked questions
What is the half-life of thymosin alpha-1?
The FDA briefing gives a serum half-life of approximately 2 hours after subcutaneous administration, and the app lists 2 hours.1 A 1999 study in 9 healthy subjects, as summarised there, reported mean elimination half-lives of 1.8 to 2.6 hours across three products, and the TESTS authors write 1.5 hours.1,2
How long does thymosin alpha-1 take to reach its peak level?
Is thymosin alpha-1 FDA approved?
How did the FDA advisory committee vote on thymosin alpha-1?
The transcript of the 4 December 2024 meeting records 4 yeses, 17 noes and 0 abstentions on the question of placing thymosin alpha-1 free base on the 503A bulks list.16
Did thymosin alpha-1 reduce deaths in sepsis in the TESTS trial?
In TESTS, 28-day mortality was 127 of 542 (23.4%) on thymosin α1 and 132 of 547 (24.1%) on placebo, and the authors report no clear evidence of a reduction.2
Does thymosin alpha-1 work for hepatitis B?
Is thymosin alpha-1 banned by WADA?
What are the reported side effects of thymosin alpha-1?
The FDA briefing gives local irritation, redness or discomfort at the injection site as the most common adverse reactions reported.1 In TESTS, adverse events occurred in 66.4% on thymosin α1 and 67.6% on placebo.2 TESTS also reported serious adverse events in 145 (26.8%) on thymosin α1 and 160 (29.3%) on placebo, and named anaemia (10.7%), fever (9.6%), abdominal distension (5.4%) and coagulation disorders (4.8%) as the most common adverse effects.2
Guides, tools and comparisons
- How to mix thymosin alpha-1A guide that answers a question on this compound.
- Calculator for Thymosin Alpha-1A calculator set up for this compound.
- Previous in Healing peptides: ThymalinThe compound before this one in the class.
- Next in Healing peptides: VilonThe compound after this one in the class.
References
- U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee (PCAC) meeting, 4 December 2024: thymosin alpha-1-related bulk drug substances. FDA briefing document
- Wu J, et al. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ 2025. PMID 39814420
- Liu J, et al. Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study. Front Immunol 2021. PMID 34408744
- Naing C, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev 2026. PMID 42713852
- Wu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care 2013. PMID 23327199
- Soeroto AY, et al. The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression. Inflammopharmacology 2023. PMID 37845598
- Kim BH, et al. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B. Scand J Gastroenterol 2012. PMID 22726105
- Lee HW, et al. Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: a prospective randomized, comparative pilot study. J Gastroenterol Hepatol 2008. PMID 18410608
- Wu X, et al. Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study. Expert Opin Biol Ther 2018. PMID 30063860
- Maio M, et al. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol 2010. PMID 20194853
- Liu F, et al. Efficacy of Thymosin α1 in Management of Radiation Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiotherapy: A Phase 2 Clinical Trial (GASTO-1043). Int J Radiat Oncol Biol Phys 2022. PMID 35870709
- Kim SD, et al. Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review. Pharmaceuticals (Basel) 2026. PMC13610580
- ClinicalTrials.gov. NCT02867267: The Efficacy and Safety of Ta1 for Sepsis (TESTS). Sun Yat-sen University. NCT02867267
- U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee (PCAC) meeting, 4 December 2024 (cover note). FDA cover note
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting, 4 December 2024: draft questions. FDA draft questions
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee, Topic 3 transcript, 4 December 2024. FDA transcript
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list